Brief: Oragenics Says Mutually Terminated Lantibiotic Agreement With Eleszto Genetika
24/09/2021 21:42
Sept 24 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS INC - ON SEPT 22, CO, ELESZTO GENETIKA, INC.
MUTUALLY
TERMINATED LANTIBIOTIC ECC AGREEMENT DATED MARCH 1, 2021
* ORAGENICS INC - CO MADE NO PAYMENTS TO EGI IN CONNECTION
WITH
MUTUAL TERMINATION
* ORAGENICS INC - WILL CEASE PRE-CLINICAL DEVELOPMENT OF ITS
PRODUCT CANDIDATE OG716 AND OTHER COMPOUNDS COVERED BY
LANTIBIOTIC ECC
* ORAGENICS - WILL FOCUS ON CONTINUING INDEPENDENT RESEARCH,
DEVELOPMENT EFFORTS RELATIVE TO LANTIBIOTICS IN ORDER TO
IDENTIFY NEW COMPOUNDS TO PURSUE
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing